within Pharmacolibrary.Drugs.ATC.V;

model V10XX03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025666666666666665,
    adminDuration  = 600,
    adminMass      = 55 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.151,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V10XX03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Radium-223 dichloride is a radiopharmaceutical agent used in the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. It is administered intravenously and delivers targeted alpha radiation to bone metastases sites. The drug is approved and used clinically under the trade name Xofigo.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with castration-resistant prostate cancer, based on population PK data from clinical trials.</p><h4>References</h4><ol><li><p>Chittenden, SJ, et al., &amp; Flux, GD (2015). A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 56(9) 1304–1309. DOI:<a href=\"https://doi.org/10.2967/jnumed.115.157123\">10.2967/jnumed.115.157123</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26182965/\">https://pubmed.ncbi.nlm.nih.gov/26182965</a></p></li><li><p>Ogawa, K, et al., &amp; Kinuya, S (2020). Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases. <i>Scientific reports</i> 10(1) 11917–None. DOI:<a href=\"https://doi.org/10.1038/s41598-020-68846-x\">10.1038/s41598-020-68846-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32681007/\">https://pubmed.ncbi.nlm.nih.gov/32681007</a></p></li><li><p>Murray, I, et al., &amp; Flux, GD (2017). The potential of . <i>European journal of nuclear medicine and molecular imaging</i> 44(11) 1832–1844. DOI:<a href=\"https://doi.org/10.1007/s00259-017-3744-y\">10.1007/s00259-017-3744-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28612079/\">https://pubmed.ncbi.nlm.nih.gov/28612079</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V10XX03;
